Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing
Reexamination Certificate
2004-10-25
2010-12-28
Kemmerer, Elizabeth C. (Department: 1649)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
C435S007950, C702S019000, C506S006000
Reexamination Certificate
active
07858071
ABSTRACT:
The invention provides a method for diagnosing amyotrophic lateral sclerosis (ALS) in a subject, a method for assessing the effectiveness of a drug in treating ALS, and a method for determining the site of onset of ALS in a subject. Each method comprises (a) obtaining a sample from the subject, (b) analyzing the proteins in the sample by mass spectroscopy, and (c) determining a mass spectral profile for the sample. In some embodiments, the method comprises comparing the mass spectral profile of the sample to the mass spectral profile of a positive or a negative standard.
REFERENCES:
patent: 5719060 (1998-02-01), Hutches et al.
patent: 5792664 (1998-08-01), Chait et al.
patent: 6294790 (2001-09-01), Weinberger
patent: 6618138 (2003-09-01), Khoury
patent: 6675104 (2004-01-01), Paulse et al.
patent: 6776984 (2004-08-01), Schwartz
patent: 7005255 (2006-02-01), Kaddurah-Daouk
patent: 7572596 (2009-08-01), Bowser
patent: 2002/0138208 (2002-09-01), Paulse et al.
patent: 2003/0013120 (2003-01-01), Patz et al.
patent: 2004/0033530 (2004-02-01), Awrey et al.
patent: 2005/0148026 (2005-07-01), Bowser et al.
patent: 2006/0121619 (2006-06-01), Bowser
patent: WO 93/24834 (1993-12-01), None
patent: WO 93/24834 (1993-12-01), None
patent: WO 98/59360 (1998-12-01), None
patent: WO 98/59360 (1998-12-01), None
patent: WO 03/006973 (2003-01-01), None
patent: WO 2006/071469 (2006-07-01), None
Lomen-Hoerth C., “Amyotrophic lateral sclerosis from bench to bedside”, Semin Neurol. Apr. 2008;28(2):Abstract.
Davidsson et al., Journal of Neural Transmission, 104:711-720, 1997.
Puchades et al., Rapid Commun in Mass Spectrom., 13:2450-2455, 1999.
Ruetschi et al., Experimental Neurology, 196:273-281, 2005.
Yang et al., Cell Mol Neurbiol., 28:737-744, 2008.
Planté-Bordeneuve et al., Curr Opin Neurol., 13(5):569-573, 2000.
Cudkowicz et al., “Measures and Markers in Amyotrophic Lateral Sclerosis,”NeuroRx: The Journal of the American Society for Experimental Neuro Therapeutics, 1(2): 273-283 (Apr. 2004).
Abrahamson et al.,FEBS Letters, 216(2), 229-233 (1987).
Borchelt et al.,Proceedings of the National Academy of Sciences of the United States of America, 91(17), 8292-8296 (1994).
Bowser et al.,The FASEB Journal, 17(4), A658 (2003).
Cleveland et al.,Nature Reviews Neuroscience, 2, 806-819 (2001).
Desnuelle et al.,Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2(1), 9-18 (2001).
Feigenbaum et al.,Artificial Intelligence, 59, 233-240 (1993).
Groeneveld et al.,Annals of Neurology, 53(4), 437-445 (2003).
Jellinger,Movement Disorders, 18(Supplement 6), S2-S12 (2003).
Kim et al.,Journal of Neuropathology&Experimental Neurology, 62(1), 88-103 (2003).
Lee et al.,Environmental Health Perspectives, 104(Supplement 5), 1059-1063 (1996).
Levy et al.,The Journal of Experimental Medicine, 169(5), 1771-1778 (1989).
Martens,FEBS Letters, 234(1), 160-164 (1988).
Menzies et al.,Brain A Journal of Neurology, 125(7), 1522-1533 (2002).
Miller et al.,Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 4(3), 191-206 (2003).
Mita et al.,Biochemical and Biophysical Research Communications, 124(2), 558-564 (1984).
Nagai et al.,The Journal of Neuroscience, 21(23), 9246-9254 (2001).
Paulson,The American Journal of Human Genetics, 64(2), 339-345 (1999).
Ranganathan et al.,Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 3(Supplement 2), 57 (2002).
Ranganathan et al.,The American Journal of Pathology, 162(3), 823-835 (2003).
Rosen et al.,Nature, 362(6415), 59-62 (1993).
Rosen et al.,Human Molecular Genetics, 3(6), 981-987 (1994).
Shaw et al.,Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 1(Supplement 2), S61-S67 (2000).
Smith et al.,Annals of Neurology, 44(4), 696-699 (1998).
Spreux-Varoquaux et al.,Journal of Neurological Sciences, 193(2), 73-78 (2002).
Subramaniam et al.,Nature Neuroscience, 5(4), 301-307 (2002).
Tsuzuki et al.,The Journal of Biological Chemistry, 260(22), 12224-12227 (1985).
U.S. Appl. No. 60/632,380, filed Dec. 2, 2004, Bowser.
U.S. Appl. No. 60/632,450, filed Dec. 2, 2004, Bowser.
Bowser, et al, “Protein Profiling of amyotrophic lateral sclerosis patients by mass spectrometry”Federation of American Societies for Exp. Bio. Annu Meeting Abstracts17:4-5(2003).
Kikuchi, et al. “Immunohistochemical analysis of spinal cord lesions in amyotrophic lateral sclerosis using microtubule-associated protein 2 (MAP2) antibodies”Acta Neuropathologica97(1)13-21(1999).
Malaspina, et al. “Differential expression of 14 genes in amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays”J. Neurochemistry77(1)132-145(2001).
Ono, et al. “Increased Cystatin C immunoreactivity in the skin in amyotrophic lateral sclerosis”Acta Neurologica Scandinavica102(1)47-52 (2000).
Pompl, et al . “Pharmacotherapeutic Biomarker Discovery in a Mouse Model of amyotrophic Lateral Sclerosis”Abstract Viewer/intinerary planner, Society of Nueroscience2002:1(2002).
Ranganathan, et al. “Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis”J. Neurochemistry95(5):1461-1471(2005).
Ranganthan, et al. “Altered expression of cell cycle regulators in amyotrophic lateral sclerosis”Society for Nueroscience Abstracts27(2):1649 (2001).
Shimizu, et al. “Detection and identification of protein variants and adducts in blood and tissues: an application of soft ionization mass spectrometry to clinical diagnosis”J. Chrom. B776(1):15-30(2002).
Abrahamson et al., “Structure and Expression of the Human Cystat in C Gene,”TheBiochemical Journal, 268(2):287-94 (1990).
Abrahamson, et al., “The human cystatin C gene (CST3), mutated in hereditary cystatin C amyloid angiopathy, is located on chromosome 20,”Hum. Genet., 82(3):223-6 (1989).
Aizawa, et al., “Basophilic cytoplasmic inclusions in a case of sporadic juvenile amyotrophic lateral sclerosis,”J. Neurol. Sci. 176:109-13 (2000).
Asgeirsson, et al., “Hereditary cystatin C amyloid angiopathy: monitoring the presence of the Leu-68—>Gln cystatin C variant in cerebrospinal fluids and monocyte cultures by MS,”Biochem. J., 329 (Pt 3):497-503 (1998).
Berg et al., “Exploring Proteins,”Biochemistry, 1-6, W. H. Freeman and Company: New York, 2002. Relevant chapter portions accessed at URL: ncbi.nlm.nih.gov/books/bv.fcgi?highlight=immunological%20techniques&rid=s- tryer.section.506#507.
Carrette, et al., “A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease,”Proteomics, 3(8):1486-94 (2003).
Deng, et al., “Elevation of cystatin C in susceptible neurons in Alzheimer's disease,”Am. J. Pathol., 159(3):1061-8 (2001).
Kato, et al., “A neurosphere-derived factor, cystatin C, supports differentiation of ES cells into neural stem cells,”Proc. Natl. Acad. Sci. U.S.A., 103(15):6019-24 (2006).
Lofberg, et al., “Immunohistochemical characterization of the amyloid deposits and quantitation of pertinent cerebrospinal fluid proteins in hereditary cerebral hemorrhage with amyloidosis,”Stroke, 18(2):431-40 (1987).
Nagai, et al., “Cystatin C and cathepsin B in CSF from patients with inflammatory neurologic diseases,”Neurology, 55(12):1828-32 (2000).
Okamoto, et al., “Bunina bodies in amyotrophic lateral sclerosis immunostaincd with rabbit anti-cystatin C serum,”Neurosci. Lett., 162(1-2):125-8 (1993).
Sanchez, et al., “Cystatin C as a potential cerebrospinal fluid marker for the diagnosis of Creutzfeldt-Jakob disease,”Proteomics, 4(8):2229-33 (2004).
Wada, et al., “Bunina bodies in amyotrophic lateral sclerosis on Guam: a histochemical, immunohistochemical and ultrastructural investigation,”Acta Neuropathol., 98(2):150-6 (1999).
Xu, et al., “Cystatin C prevents degeneration of rat nigral dopaminergic neurons: in vitro and in vivo studies,”Neurobiol. Di
Bowser Robert P.
Ranganathan Srikanth
Kemmerer Elizabeth C.
MacFarlane Stacey
Pabst Patent Group LLP
University of Pittsburgh—Of the Commonwealth System of Hi
LandOfFree
Biomarkers for amyotrophic lateral sclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biomarkers for amyotrophic lateral sclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biomarkers for amyotrophic lateral sclerosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4202532